Financing efficient HIV care and antiretroviral treatment to mitigate the impact of the AIDS epidemic on economic and human development

Jean-Paul Moatti, Tony Barnett, Yves Souteyrand, Yves-Antoine Flori, Jérôme Dumoulin () and Benjamin Coriat ()
Additional contact information
Jérôme Dumoulin: LEPII - Laboratoire d'Economie de la Production et de l'Intégration Internationale - UPMF - Université Pierre Mendès France - Grenoble 2 - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: This text presents the second part of the book. In the first two decades of the HIV Epidemic, the strategy in developing world was focused on preventive methods. The challlenge is now give HIV treatment access for the benefit of People Living With HIV/Aids (PLWH) and for curbing the epidemic. Experiences in Brazil, Chile, Thailand are implemented to achieve this goal. In some African countries as Cote d'Ivoire, Senegal and Uganda, pilot projects have proved the feasibility and efficency of Antiretroviral treatments in subsaharian countries. These experiences show that a strong involvement of governments to promote or to regulate the delivery of ARV drugs is needed to face an eventual "antiretroviral anarchy". Scaling up access to ART will often take place in a context of failing government systems. The economic arguments against access to HIV treatment in developing countries are critically reviewed and the book brings evidence that treatment is rational as economic decision. Furthermore, the books stands the economic impact of the epidemic is underestimated with a new conceptual approach which highlights the "involution trap" where countries can fall in the long run. Some "optimistic" results of previous models, as a reduced pressure on land and capital, are artefacts. So the main rationale of HIV Treatment is to prevent falling in this trap : more resources must be allocated to scaling up programs. The book shows how countries can mobilize new resources. Every country must find the best balance between public subsidies, private insurance, private fundings and patients participation.

Keywords: AIDS; developing countries; drug; treatment; SIDA; Pays en Voie de Développement; médicament; coût; efficacité; financement; traitement médical (search for similar items in EconPapers)
Date: 2003
References: Add references at CitEc
Citations:

Published in Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.A. Economics of AIDS and access to HIV/AIDS care in developing countries : issues and challenges, Agence Nationale de Recherche sur le SIDA, pp.247-265, 2003, Sciences Sociales et SIDA

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-00112030

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().